2 recruiting, 1 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow CSB-001 Ophthalmic Solution 0.1%: new trials by email Literature Review of CSB-001 Ophthalmic Solution 0.1% trials Research Report on CSB-001 Ophthalmic Solution 0.1%
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency CSB-001 Ophthalmic Solution 0.1% - Limbal Stem Cell Deficiency | Phase 1 | Recruiting | Claris Biotherapeutics, Inc. | 75 | 2024-05-15 | 2026-08-13 |
| Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars CSB-001 Ophthalmic Solution 0.1% - Corneal Scar | Phase 1 | Recruiting | Claris Biotherapeutics, Inc. | 20 | 2024-02-05 | 2026-04-07 |
| Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects CSB-001 Ophthalmic Solution 0.1%, Vehicle Control - Neurotrophic Keratitis | Phase 1 / Phase 2 | Completed | Claris Biotherapeutics, Inc. | 131 | 2021-08-24 | 2026-05-13 |
Corneal Injuries (1) · Limbal Stem Cell Deficiency (1)
Claris Biotherapeutics, Inc. (3)
United States (3) · Canada (1)